Wednesday, May 8, 2019 The Palace at Somerset Park, Somerset, NJ www.BioNJ.org Ninth Annual Co-Sponsors Innovation on the Rise New Partnering Paradigms & Pathways
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Wednesday, May 8, 2019The Palace at Somerset Park, Somerset, NJ
www.BioNJ.org
Ninth Annual
Co-Sponsors
Innovation on the RiseNew Partnering Paradigms & Pathways
Welcome to BioNJ’s 2019 BioPartnering Conference,
On behalf of BioNJ, J.P. Morgan and Johnson & Johnson Innovation, it is our honor to welcome you to the Ninth Annual BioPartnering Conference, “Innovation on the Rise: New Partnering Paradigms & Pathways.”
We are excited to bring together biopharmaceutical executives, investors, academic collaborators and business development professionals from the Northeast to Mid-Atlantic for a day of 1:1 partnering meetings, in-depth plenary sessions, exhibits and posters, networking and company presentations. Today is about growing the ecosystem and partnering to bolster medical innovation.
The program is designed to foster productive partnerships, create fruitful opportunities and support the valuable work you do to bring hope to Patients around the world.
There are many people to thank for their contributions in getting us to this important day, beginning with our speakers, judges, exhibitors, supporting partners and generous sponsors who have supported this initiative in exceptional ways.
We are grateful to our panel of industry experts who are leading the plenary discussions. Additionally, we are appreciative of the world-renowned regional institutions exhibiting today, reminding us of the critical role industry and academic collaboration plays in driving innovation. And finally, a special thank you to the BioPartnering Conference Planning Team Members who have given so freely of their time and talent during the last several months to transform a vision from concept to reality.
We hope you come away from today’s conference with new collaborations, partnerships and inspiration that will lead to future innovation. Thank you forbeing here.
Because Patients Can’t Wait®,
1
WELCOMENinth Annual
Alma DeMetropolis, CFA, CFP® Managing Director Market Manager President, New Jersey Market Leadership Team J.P. Morgan Private Bank
Debbie HartPresident and CEOBioNJ
William N. Hait, M.D., Ph.D.Global Head, Johnson & Johnson External Innovation
7:30 a.m.-8:40 a.m. REGISTRATION & NETWORKING BREAKFAST
8:40 a.m.-9:00 a.m. WELCOME & OPENING REMARKS
Debbie Hart, President & CEO, BioNJ
9:00 a.m.-9:30 a.m. AN INDUSTRY UPDATE AND TRENDS OVERVIEW
Robert Huffines, Global Chairman, Investment Banking, J.P. Morgan
9:30 a.m.-10:20 a.m. DIVERSE NEW PATHWAYS TO STRATEGIC PARTNERING
Chip Baird, Chief Financial Officer, bluebird bio
Matthew Roden, Ph.D., Head, Strategic Corporate Development & Global Business Development Assessment, Bristol-Myers Squibb
Debi Watson, Head, Oncology Business Development Group, Johnson & Johnson Innovation, Janssen Business Development
MODERATED BY: John Whittaker, MBA, Executive Director Healthcare Investment Banking, J.P. Morgan
10:30 a.m.-12:00 p.m. COMPANY PRESENTATIONS AND PARTNERING MEETINGS
12:00 p.m.-12:30 p.m. NETWORKING, COMPANY PRESENTATIONS Q&A, PARTNERING MEETINGS AND EXHIBITS
2 3
12:30 p.m.-1:20 p.m. NETWORKING LUNCHEON
1:20 p.m.-1:50 p.m. FIRESIDE CHAT: PAVING PATHWAYS TO A “WORLD WITHOUT DISEASE”
William N. Hait, M.D., Ph.D., Global Head, Johnson & Johnson External Innovation
IN CONVERSATION WITH:Debbie Hart, President & CEO, BioNJ
2:00 p.m.-3:30 p.m. COMPANY PRESENTATIONS AND PARTNERING MEETINGS
2:00 p.m.-3:30 p.m. INSTITUTION/START-UP TRACK: INVESTOR PANEL DISCUSSION AND PITCH PRESENTATIONS (SALON 4)
Sonia Gulati, Ph.D., Executive in Residence Kairos Ventures
Edward Rosen, Founder, Glendevon Life Sciences
Donald Very, Ph.D., Chief Technical Analyst, Devices and Diagnostics, Velocity Fund Management, LLC
Michael Wiley, Vice President, New Jersey Health Foundation/Foundation Venture Capital Group, LLC
MODERATED BY:Michal Preminger, Ph.D., MBA, Head, Johnson & Johnson Innovation, East North America
3:30 p.m.-4:00 p.m. NETWORKING, COMPANY PRESENTATIONS Q&A, PARTNERING MEETINGS AND EXHIBITS
4:00 p.m.-4:30 p.m. FIRESIDE CHAT: PARTNERING IMPERATIVES AND NAVIGATING TO COMMERCIALIZATION
Brian Flood, Managing Director, J.P. Morgan
Patrik Ringblom, Global Commercial Strategy Leader for Oncology, Janssen Global Services
4:30 p.m. CLOSING REMARKS
Debbie Hart, President & CEO, BioNJ
CONFERENCE AGENDA CONFERENCE AGENDA
Wednesday, May 8, 2019
Ninth Annual
Co-Sponsors
www.BioNJ.org
Columbia University Maria Rahmany, Ph.D., MBA, Business Development Columbia Technology Ventures [email protected]
Coriell Institute for Medical Research Ellen M. Kelly, Ph.D., Program Director [email protected]
Hackensack Meridian HealthSandra Elliott, Vice President, Life Sciences & InnovationPhysician Enterprise [email protected]
Johns Hopkins University Hassan Naqvi, Director, Corporate Partnerships [email protected]
New Jersey Institute of TechnologyHaro Hartounian, Executive Director Biotechnology and Pharmaceutical Innovation, iLab Development [email protected]
New York UniversityAbram Goldfinger, Executive Director Industrial Liaison/Technology [email protected]
Princeton UniversityDean R. Edelman, Corporate Engagement & Foundation Relations [email protected]
Rutgers, The State University of New JerseyVincent Smeraglia, Executive Director of Strategic AlliancesTranslational [email protected]
Rowan UniversityJeanne Nevelos, Managing Director, Rowan [email protected]
Stevens Institute of TechnologyDavid Zimmerman, Director of Technology [email protected]
University of PennsylvaniaViviane Martin, Ph.D., Director, Perelman School of Medicine Penn Center for [email protected]
The Wistar InstituteHeather A. Steinman, Ph.D., MBA, Vice President Business Development & Executive Director, Technology Transfer The Wistar [email protected]
4
INDUSTRY SHOWCASE
www.fishersci.com
5
INSTITUTION EXHIBITORS
www.scientist.com
www.bezwadabiomedical.com
www.labowl.com
www.andersentax.com
www.cannoncassidy.com www.coretelligent.com
www.nucleusnetwork.com.au
www.sharevault.com
www.scisafe.com
www.springernature.com
www.rsmus.com
www.bio.org
www.connorstrong.com
www.eisneramper.com www.friedmanllp.com
www.leaderstrong.com
www.ipmcinc.com
www.withum.com
www.unifirst.com
www.jpmorgan.com www.jnjinnovation.com
6
MAP | 1st FLOOR
7
MAP | 2nd FLOOR
John Whittaker, MBA Executive Director, Healthcare Investment Banking, J.P. Morgan
Mr. Whittaker is a Executive Director in the Healthcare Banking Group at J.P. Morgan. He focuses primarily on life sciences clients in the pharmaceutical and biotechnology space, including animal health companies. Mr. Whittaker has worked on numerous M&A assignments, IPOs and equity follow-on
offerings as well as investment-grade debt offerings. M&A assignments include both buy-side and sell-side transactions with public and private companies. Currently based in New York, he spent several years working with the JPM Healthcare team in London covering European clients.
Debi Watson Head, Oncology Business Development Group Johnson & Johnson Innovation, Janssen Business Development
In her role, Ms. Watson leads Business Development Strategy in coordination with Oncology R&D and Commercial Leadership. She is responsible for all aspects of licensing, search and evaluation, M&A
and alliance management for the Janssen Oncology Therapeutic area. Under Ms. Watson’s leadership, the oncology team has executed several important transactions, including the recent BCMA CAR-T/Legend deal, niraparib/TESARO, Imetelstat/Geron and two deals with MacroGenics. With her guidance, the oncology team manages several significant alliances, including the Ibrutinib alliance with Pharmacyclics/Abbie and Daratumumab with Genmab.
8
SPEAKERS
Welcome & Opening RemarksDebbie Hart President & CEO, BioNJ
Ms. Hart worked alongside NJ’s biotechnology industry leaders to establish BioNJ in 1994. She was recently named by Governor Murphy to the NJ Commission on Science, Innovation and Technology; as co-chair of the NJ Higher Education Strategic Plan Research, Innovation and Talent Working
Group; and the NJ Commission on Higher Education and Business Partnership. Ms. Hart served as chair of the NJ Biotechnology Task Force, is a founding board member and officer of OpportunityNJ and serves on the boards of the NJ Chamber of Commerce and Choose New Jersey. Ms. Hart was named one of the world’s 100 Most Influential People in Biotechnology by Scientific American Worldview.
An Industry Update and Trends OverviewRobert Huffines Global Chairman, Investment Banking, J.P. Morgan
Mr. Huffines joined J.P. Morgan in 1991. He joined in the Mergers and Acquisitions Group, where he was healthcare focused. From 2002 – 2010, Mr. Huffines was Co-Head of the Global Healthcare Investment Banking Group. In 2011, he was promoted to Vice Chairman to deepen the firm’s
relationships with significant clients. In 2017, Mr. Huffines was added to the Global Banking Management Team and named Co-Chair of the Global Strategic Advisory Council. Prior to joining J.P. Morgan, Mr. Huffines worked at Alex Brown & Sons.
Diverse New Pathways to Strategic Partnering
Fireside Chat: Paving Pathways to a “World Without Disease”
Chip Baird Chief Financial Officer, bluebird bio
Mr. Baird joined bluebird bio in February of 2019. He has over 20 years of financial and strategic planning experience in the biopharmaceutical sector. Prior to bluebird bio, he served as CFO of Amicus Therapeutics for seven years and spent 10 years as CFO of PTC Therapeutics with responsibility
for all areas of finance, investor and public relations, human resources, facilities and project management. Mr. Baird also worked in the life sciences practice at L.E.K. Consulting and at First Union National Bank. He currently serves as a Director of Axcella Health.
9
SPEAKERS
William N. Hait, M.D., Ph.D.Global Head, Johnson & Johnson External Innovation
Dr. Hait leads the external sourcing and creation of transformational innovation to help Johnson & Johnson achieve its mission to change the trajectory of health for humanity. He works on building an enterprise-wide external R&D pipeline, creating innovative solutions that utilize
J&J’s excellence in pharmaceuticals, medical devices and consumer products. His team strives to identify disruptive technologies and cutting-edge early innovations in disease areas of emphasis at J&J, to eliminate disease through prevention, interception and cures. Before joining J&J, Dr. Hait was the founding Director of The Rutgers Cancer Institute of New Jersey.
Matthew Roden, Ph.D. Head, Strategic Corporate Development & Global Business Development Assessment, Bristol-Myers Squibb (BMS)
At BMS, Dr. Roden oversees the Global Mergers & Acquisition team accountable for acquisitions, structured transactions, strategic equity investing and divestitures, as well as leading Business Development Search
and Evaluation activities for all therapeutic categories. Prior to joining BMS, he was Head of Biotechnology Equity Research at UBS Investment Bank. Earlier, he was a Senior Equity Analyst covering biotechnology at J.P. Morgan and Bank of America Merrill Lynch, and was an Associate at Credit Suisse First Boston. Dr. Roden serves on the BioNJ Board of Trustees.
Alma DeMetropolis, CFA, CFP® Managing Director, Market Manager President, New Jersey Market Leadership Team J.P. Morgan Private Bank
Ms. DeMetropolis provides executive leadership across our firm’s lines of business as well as both community and employment engagement. She
has been advising families, endowments and foundations on a broad range of wealth matters and managing investment portfolios for over 20 years and joined J.P. Morgan in 1992. Ms. DeMetropolis is on the boards of the Liberty Science Center, the Community Food Bank of New Jersey, New Jersey Performing Arts Center, SciTech Scity and Nature Conservancy NJ Advisory Council.
10 11
SPEAKERSSPEAKERS
Brian Flood Managing Director, J.P. Morgan
Mr. Flood provides advice on a wide range of investment solutions for a diverse client base including ultra-high net worth families, financial principals, private foundations and endowments. His responsibilities include advising clients on asset allocation and constructing investment
portfolios utilizing both traditional and alternative investments. Mr. Flood joined J.P. Morgan in 1998 as a Fixed Income Product Specialist focusing on the tax exempt bond market. He later joined the Northeast business as a sales trader, concentrating on brokerage solutions for private clients in the New York Metropolitan Area.
Fireside Chat: Partnering Imperatives and Navigating to Commercialization
Edward Rosen Founder, Glendevon Life Sciences
Mr. Rosen is a serial entrepreneur with a foundation of success in multi-national drug, device and diagnostic companies. He is the Founder and Managing Partner of Glendevon Life Sciences LLC, an early stage fund and accelerator bridging academia and Series A funding. Mr. Rosen is also
currently an Executive in Residence for the Technology Ventures Group at Columbia University. He was the founding CEO, President and Director of Elucida Oncology, Inc. and has a passion towards driving companies and the people within to fulfill their true potential.
Sonia Gulati, Ph.D. Executive in Residence, Kairos Ventures
Dr. Gulati has a broad background in life sciences venture capital, strategy consulting and basic science research. As an EIR, she works closely with founding scientists and their teams to develop and execute a commercialization strategy in order to help companies reach key
commercial milestones. Prior to joining Kairos Ventures, Dr. Gulati was an Assistant Director at New York Ventures. Before New York Ventures, she worked at a boutique healthcare consultancy where she helped biotechnology and pharmaceutical companies meet their commercial development goals by informing their product launch and life cycle management strategies.
Investor Panel Discussion
Donald Very, Ph.D. Chief Technical Analyst, Devices and Diagnostics Velocity Fund Management, LLC
With over 30 years of diagnostic and pharmaceutical assay development and performance qualification experience in such diverse clinical areas as oncology, infectious disease and metabolic disease, Dr. Very has extensive
experience in all phases of diagnostic assay research, development, performance validation, clinical trial design and implementation and regulatory approval. In addition to his position at Velocity Fund Management, LLC, Dr. Very is also President, CEO and Founder of Naviter Bioanalytics, LLC, a private consulting firm specializing in biomedical technology evaluation, bioanalytical method development, performance qualification and regulatory approval.
Michael Wiley Vice President, New Jersey Health Foundation/Foundation Venture Capital Group, LLC
The New Jersey Health Foundation and its affiliate, Foundation Venture Capital Group, LLC, provide funding and/or pre-seed investments for health-related projects and start-up companies founded by researchers
at the following affiliated organizations: Kessler Foundation, New Jersey Institute of Technology, Princeton University, Rowan University, Rutgers University and Stevens Institute of Technology. Mr. Wiley assists the Foundation Venture Capital Group’s health-related portfolio companies by providing funding and assisting with the various strategic, operational and back office management issues associated with developing and growing early stage health-related companies.
Patrik Ringblom Global Commercial Strategy Leader for Oncology, Janssen Global Services
Mr. Ringblom is responsible for setting and executing the oncology strategy, building disease area strongholds and business development. He has direct responsibility for a fully integrated team, including
dedicated resources in strategic marketing, strategic analytics, market access, medical affairs and business development. Mr. Ringblom played an important part rolling out the 2020 Roadmap and secured that the Disease Area Stronghold model became a success. During his time in oncology, Janssen has become the 4th largest oncology company (previously 15th largest) with a best-in-class portfolio for the future of Patients with prostate, lung and hematology cancers.
Michal Preminger, Ph.D., MBA Head, Johnson & Johnson Innovation, East North America
Dr. Preminger oversees a portfolio of co-investments and collaborations spanning across pharmaceutical, consumer health and medical devices and oversees the construction, prioritization and advancement of the External R&D portfolio for the Boston Innovation Center. She previously served as
the Executive Director of Harvard University’s Office of Technology Development, Harvard Medical School site, where she negotiated license agreements with major biopharma, life sciences, food and cosmetics companies to create a revenue-generating product pipeline. Prior to Harvard, Dr. Preminger held a number of business and technology development positions at Compugen.
12 13
THANK YOU TO OUR SPONSORS THANK YOU TO OUR SPONSORS
Company Presentation Sponsors
Partnering Professionals Breakfast Sponsor
Partnering Area Sponsors
Institution Alley Sponsors
Exhibit Sponsors
1514
SPONSOR PROFILES SPONSOR PROFILES
Ashton Tweed
Ashton Tweed’s executive talent bank provides your company highly experienced executives and life sciences industry experts ready for interim or permanent placement. When you partner with Ashton Tweed, you benefit from our deep understanding of the life sciences market and connection to the pharmaceutical, biotechnology, diagnostic and medical device sectors. Whether you are or you require executive or management talent — interim, permanent or interim to hire — Ashton Tweed can meet your specialized retained search needs.
Andersen Tax
Andersen Tax delivers a full range of value-added and cost effective services to our clients. We take the time to understand the intricacies of each individual and business so that we can tailor our service to each client’s unique situation. Andersen Tax is the founding member of Andersen Global, an international association of legally separate, independent member firms with more than 4,000 professionals worldwide, over 500 global Partners, and a presence in over 138 locations through its member firms and collaborating firms.
Amicus Therapeutics
Amicus Therapeutics is a global, Patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases.
BIO
BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Mark your calendar for the convention in Philadelphia, PA June 3-6, 2019.
Bezwada Biomedical
Bezwada Biomedical is an innovation driven start-up company catering to the unmet needs of the biomaterial community and medical device industry. With our state-of-the-art research and development facilities in the U.S. and India, combined with our platform technologies derived from a family of novel and proprietary biodegradable polymeric biomaterials, we work with and for our customers to translate their demands into high-quality products for a wide range of medical device and therapeutic applications in a cost effective manner.
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help Patients prevail over serious diseases. Our medicines are helping millions of people around the world in their fight against serious disease.
CannonCassidy
CannonCassidy is a global naming consultancy providing strategic and creative branding services to the pharmaceutical, biotechnology, medical device, consumer and industrial sectors. Services include brand name/trademark development, USAN/INN name development, clinical trial naming, platform technology naming, legal and regulatory screening, POCA analysis, name validation research, linguistic analysis and visual identity/logo development. FDA, EMA, Health Canada Regulatory Expertise.
Conner Strong
Conner Strong is a leader in risk management, insurance and employee benefits within the life sciences arena. Our dedicated team of professionals exclusively services the complex insurance needs of the life sciences community on a national and global scale. We know science, and just as importantly, we know your process. Our approach is part experience, part process and all partnership.
Coretelligent
Coretelligent is a leading provider of comprehensive managed IT, cyberecurity and cloud services, enabling organizations to seamlessly power and successfully grow their businesses. Founded in 2006 and led by world-class experts, Coretelligent’s key services — managed IT, cybersecurity and cloud solutions — are relied on by top-tier organizations in the financial services, life sciences, legal and technology industries. Coretelligent’s team is recognized as leaders by CRN, Inc., MSPmentor and the U.S. Chamber of Commerce.
EisnerAmper
EisnerAmper’s Life Sciences Practice professionals have the expertise, resources and relationships to assist both public and private life sciences companies bridge the gap between business and science. In addition to the traditional tax and accounting services, EisnerAmper also assists our life sciences clients with services such as internationalization, cybersecurity, process automation, SOX and more.
Friedman LLP
Friedman LLP has been serving the accounting, tax and business consulting needs of public and private companies since 1924. Our Life Sciences Services Practice enables life sciences companies and their bio-entrepreneurs, at every stage of their life cycle, to do what they do best: innovate and work creatively. As that occurs, you can be assured that the complex and nuanced accounting, reporting and tax compliance issues associated with capital, financing, licensing and other collaborative arrangements are effectively managed.
Haug Partners
Haug Partners is a full-service, national law firm that provides integrated multidisciplinary legal services for life sciences and technology companies. Our service offerings include: (i) Antitrust Litigation and Counseling; (ii) Commercial Litigation and Strategic Counseling; (iii) Due Diligence; (iv) FDA Compliance and Counseling; (v) Intellectual Property Enforcement; (vi) Intellectual Property Procurement and Strategy; (vii) International Trade Commission; (viii) Investigations, Compliance and Risk Mitigation Services; (ix) Licensing and Transactions and (x) Trademarks and Unfair Competition.
Integrated Project Management Company, Inc. (IPM)
Integrated Project Management Company, Inc. (IPM) is a business consulting firm focused on planning and implementing strategically critical initiatives. For more than 30 years, IPM has managed thousands of projects for more than 150 biotech, pharmaceutical and medical technology companies, as well as in the healthcare, consumer products and industrial sectors. Consultants work with the cross-functional experts of our clients, which range from start-ups to some of the world’s largest firms. Headquartered in Chicago, IPM has regional offices in Parsippany, Boston, St. Louis, Los Angeles, San Francisco and Minneapolis.
16 17
SPONSOR PROFILES SPONSOR PROFILES
New Jersey Health Foundation
New Jersey Health Foundation supports health-related research and education programs in New Jersey through its Research Grant Program, Innovation Grant Program and its affiliate, Foundation Venture Capital Group, which provides pre-seed investments to help health-related start-up companies established by researchers at Kessler Foundation, New Jersey Institute of Technology, Princeton University, Rowan University, Rutgers University and Stevens Institute of Technology advance toward commercialization.
Nucleus Network
Nucleus Network (NN) is Australia’s only multi-site dedicated Phase I CRO located in Melbourne (80 beds) and Brisbane (62 beds). The facilities are strategically co-located within the Alfred Hospital in Melbourne and the Royal Brisbane and Women’s Hospital in Brisbane. This provides NN with access to a combined population of 7.5 million people. Since 2004, NN has conducted over 750 studies, with 90% of clients being overseas pharmaceutical and biotech companies. NN runs approximately 70 studies per year, with around 30 of these being true first-in-human studies.
Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.
Princeton Innovation Center BioLabs
Princeton Innovation Center BioLabs is a vibrant meeting place for members of the New Jersey science community. The new center for science entrepreneurs was launched in partnership with Princeton University. The Center includes fully supported and equipped dedicated science co-working, meeting and event space for high potential early stage companies. There is wet lab space for chemical, biological and pharmaceutical development and dry lab space for engineering development. Princeton Innovation Center BioLabs is part of BioLabs’ network of facilities that is helping to change the way science companies are created.
RSM US LLP
RSM US LLP is the U.S. member of RSM International, a global network of independent audit, tax and consulting firms with more than 41,000 people in 116 countries. RSM’s purpose is to deliver the power of being understood to our clients, colleagues and communities through world-class audit, tax and consulting services focused on middle market businesses. We have advised life sciences companies in all stages; assisting during scientific discovery, development, financing, regulatory approval, intellectual property monetization, IPOs, structuring and M&As.
Scientist.com
Scientist.com is the world’s largest marketplace for outsourced research services. For over a decade Scientist.com has connected global research organizations with commercial research organizations (CROs) to simplify research outsourcing. The marketplace is a source-to-pay platform that saves researchers time, reduces costs, provides access to the latest research innovations and ensures regulatory compliance.
Johnson & Johnson Innovation
Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. We connect with innovators through our regional Innovation Centers; Johnson & Johnson Innovation – JLABS; Johnson & Johnson Innovation – JJDC, Inc.; and our Janssen business development teams.
J.P. Morgan
J.P. Morgan Life Sciences bankers are dedicated to delivering financial solutions tailored to your needs. From early-stage startups to multinational corporations, we understand the unique challenges life science companies face at every stage of their life cycle. Our national footprint enables us to provide access to vital industry networks and leverage firm-wide expertise while helping guide your company as it navigates the regulatory environment and FDA approval process.
Lab Owl™
Lab Owl™ is a flexible and fully integrated bioreactor control system for cell culture and fermentation applications. Available in a variety of form factors, Lab OwlTM features an easy-to-use interface that has been leveraged in applications ranging from benchtop bioreactors in development labs through pilot plants and manufacturing.
LeaderStrong
LeaderStrong is a boutique New Jersey-based leadership consulting, strategic advisory and executive coaching firm on a mission to dramatically increase the leadership impact of the high-tech and biotech clients we serve in the New York to Philadelphia corridor. LeaderStrong helps clients increase the velocity and relevance of their organizations through our thought leadership in our proven and proprietary methodologies. Our highly tailored leadership programs enable our clients to get the hard hitting business results they desire.
McCarter & English
McCarter & English delivers strategic legal counsel to life sciences clients in every phase of their life cycle. Our team of 130 intellectual property lawyers and professionals — including 30+ Ph.D.s in the disciplines that drive the industry — regularly collaborate to advise enterprises in IP portfolio management, transactions and dispute resolution. From the world’s largest pharmaceutical and medical device companies to research universities, leading-edge start-ups and the investors who fund them, our clients trust us to bring the innovative solutions required to assure their success in this highly complex marketplace.
Merck & Co.
Merck & Co. has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. With more than 100 significant business development transactions since 2017, our team has experience working on collaborations from discovery through clinical-stage programs. We believe that by working together we can play a major role in transforming global healthcare. Together we can invent for life. Learn more at merck.com/licensing.
18
SPONSOR PROFILES
SciSafe
SciSafe offers dedicated pharmaceutical, biological, and consumer products sample management services in its fully cGMP compliant state-of-the-art facilities. SciSafe stores over 30,000,000 of our client’s most precious and valuable samples in over 300 freezers and walk in rooms. Our state-of-the-art facilities are located throughout the U.S. We are currently expanding to service the ever-increasing global market. We offer everything from cold chain delivery to cold storage in our New Jersey and Massachusetts facilities.
ShareVault
ShareVault’s secure document sharing solution enables organizations to protect, manage and share confidential information. Endorsed by BIO and 49 affiliates, ShareVault’s life sciences functions have been used to support multiple applications, including business transaction due diligence for M & A, in/out licensing, IPO, asset sale, fundraising, technology transfer and buy side deals; confidential information sharing for partnering, alliance collaboration, CRO/CMO collaboration, board members, investors, consultants, vendors, attorneys; secure storage and efficient viewing of regulatory eCTD submissions and electronic trial master file (eTMF) sharing and review and consolidation of document silos using connectors to SharePoint/Office365, Box, Dropbox and Docusign e-signature.
Springer Nature
Springer Nature is one of the world’s leading global research, educational and professional publishers, home to an array of respected and trusted brands providing quality content through a range of innovative products and services. Springer Nature is the world’s largest academic book publisher and numbers almost 13,000 staff in over 50 countries.
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $23 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve Patient diagnostics, deliver medicines to market and increase laboratory productivity.
Toppan Merrill
Toppan Merrill is a leader in financial printing and communication solutions and has been a pioneer and trusted partner to the financial, legal and corporate communities for five decades, providing secure, innovative solutions to complex content and communications requirements. Through proactive partnerships, unparalleled expertise, continuous innovation and unmatched service, Toppan Merrill delivers a hassle-free experience for mission-critical content for capital markets transactions, financial reporting and regulatory disclosure filings, and marketing and communications solutions for regulated and non-regulated industries.
Withum
Withum is a forward-thinking, technology-driven advisory and accounting firm, committed to helping clients be more profitable, efficient and productive in the modern business landscape. As an independent member of HLB, the global advisory and accounting network, Withum serves businesses and individuals on a local-to-global scale. Our specialists engage with pharmaceutical, biotech and medical device companies to help navigate the business issues unique to their industry and stage of their life cycle. Our professionals provide the expert advice and innovation solutions you need to Be in a Position of StrengthSM in today’s fast-paced, tech-driven world.
THANK YOU TO OUR SPONSORS
THANK YOU TO OUR SUPPORTING PARTNERS
21
THANK YOU TO OUR PANEL OF JUDGES
Michael Baran, Pfizer
Tom Brennan, ARCH Venture Partners
Kathleen Coviello, New Jersey Economic Development Authority
Hope D’Oyley Gay, Militia Hill Ventures
James Golubieski, New Jersey Health Foundation
Jim Gunton, Tech Council Ventures
Shahram Hejazi, BioAdvance
John Prendergass, Ben Franklin Technology Partners of Southeastern PA
Gloria Rabinowitz, Golden Seeds
Jorge J. Ramirez, H.I.G. BioHealth Partners
Bernie Rudnick, CapGenic Advisors
Robert Sawicki, Frontcourt Group
Yaniv Sneor, MidAtlantic Bio Angels (MABA)
Nishit Trivedi, Emerald Asset Management
Michael Wells, Princeton BioPharma Capital Partners, LLC
Tim Whitten, Taiho Ventures, LLC
Ido Zairi, Israel Biotech Fund
THANK YOU TO OUR CONFERENCE CO-SPONSORS
J&J INNOVATION
Tom Cavanaugh, President Oncology, Janssen
Charlie Knights, Director, Janssen Business Development
Juan Ruiz, Director, U.S. New Products and Business Development, Janssen
Erin Walsh, Communications Leader, Johnson & Johnson Innovation
J.P. MORGAN
Kathleen Addison, Executive Director, Life Sciences
Dana D’Amelio, Private Banker
Alma DeMetropolis, CFA, CFP®, Managing Director, Market Manager, President, New Jersey Market Leadership Team, J.P. Morgan Private Bank
Kenneth Freelund, Executive Director
Robert Huffines, Global Chairman, Investment Banking
Peter Meath, Managing Director, Industry Head Life Sciences
Joseph Mellusi, CFA, Vice President
Stephen Van Besien, Managing Director, Private Bank
John Whittaker, MBA, Executive Director, Heathcare Investment Banking
THANK YOU TO OUR PLANNING TEAM
Kathleen Addison, Executive Director, Life Sciences, J.P. Morgan
Corey Andrews, Solutions Engineer, Merrill Datasite
Timothy Atkins, Partner, Pepper Hamilton, LLP
Tom Cavanaugh, President Oncology, Janssen
Dana D’Amelio, Private Banker, J.P. Morgan
Ben Davis, Vice President, Corporate Alliances, IQVIA
Neal Davies, Sr. Vice President, Merrill Datasite
Dean Edelman, Corporate Engagement and Foundation Relations, Princeton University
Sandra Elliott, Vice President, Life Sciences and Innovation, Hackensack Meridian Health
Jean Gardner, Senior Vice President, Merrill Datasite
Joshua Goldberg, Partner, Nath, Goldberg & Meyer
Michael Hadjiloucas, Partner-In-Charge, Corporate Tax Group, EisnerAmper, LLP
Juliet Hart, Principal, Hart & Chin Associates, LLC
Benjamin Hoffman, Ph.D., Senior Manager, Oncology Transactions Janssen Business Development
Susan Kinda, Sales Director, Merrill Datasite
Jack Levitt, Co-Founder, LeaderStrong
Beverly Lubit, Ph.D., Partner, McCarter & English, LLP
Scott T. Megaffin, Chief Executive Officer, Adastra Pharmaceuticals
Joseph Mellusi, CFA, Vice President, J.P. Morgan
John Pennett, Partner-in-Charge, Life Sciences Group, EisnerAmper, LLP
Ravi Raghunathan, CPA, Partner, Life Science Industry Leader, CohnReznick
Emilio Ragosa, Partner, DLA Piper
Judith Sheft, Associate Vice President, Technology & Enterprise Development, NJIT
Vincent Smeraglia, Executive Director, Rutgers, The State University of New Jersey Office of Research Commercialization
Arda Ural, Ph.D., Partner, Life Sciences, Transaction Advisory Services, Ernst & Young, LLP
Stephen Van Besien, Managing Director, Private Bank, J.P. Morgan
Erin Walsh, Communications Leader, Johnson & Johnson Innovation
Jordan Warshafsky, Partner, Ashton Tweed, LTD
David Zwally, Partner, Haug Partners, LLP
20
IMPORTANT UPCOMING BioNJ EVENTS
Visit www.BioNJ.org often for calendar updates, or email [email protected] for more information.
*Invitation only event.
MAYMay 16: Finance Forum
JUNEJune 3-6: BIO 2019 International
Convention
JULYJuly 18: New X2 BioCruise with
NewYorkBIO
SEPTEMBERSept. 20:
Sept TBD:
Manufacturing Breakfast Briefing
Legal, Compliance & Regulatory Forum
OCTOBEROct 4:
Oct TBD:
Oct TBD:
Patient Advocacy Summit
Human Resource Conference
Clinical Development
NOVEMBERNovember 8:
November TBD:
November TBD:
C-Suite Summit
Human Resource Forum
Breakfast with BioNJ
DECEMBERDecember 6:
December TBD:
December TBD:
Inspiring Women in STEM Conference
Legal, Compliance & Regulatory
Forum Legislative Holiday Reception*
FEBRUARY 2020February 6: Annual Dinner
Meeting & Innovation Celebration
JOIN THE CONVERSATION
Connect with BioNJ on social media for the latest news on New Jersey’s
vibrant life sciences ecosystem.
Plus, learn about upcoming BioNJ events and networking opportunities.
Twitter @BioNJ_Org
www.facebook.com/BioNJ
www.youtube.com/BioNJvideos
linkedin.com/company/BioNJ
23
Protecting Medical Innovation & Making a Difference Together
The Value of BioNJ Membership
In these ever-changing times, it has never been more important to be informed, involved and forward-looking. BioNJ Membership offers the tools, resources and platforms that you and your organization need to be all three.
Whether large or small, your company will benefit from BioNJ Membership through the following areas:
• Advocating for public policy decisions that encourage future investment in medical innovation and ensure Patient access to the therapies and cures that they need
• Hosting over 35 events each year, offering networking, learning and thought leadership
• Providing tools and resources to grow your business and help you save money on important services
• Offering unique ways to expand your visibility and build brand recognition
• Helping you find the talent that you need
Visit www.BioNJ.org to learn how BioNJ’s programs and services can help your organization help Patients. Or, call
Kim Minton at 609-890-3185 for more information.
BioNJ TEAM
BioNJWhitehorse Executive Center
1255 Whitehorse-Mercerville RoadBuilding B - Suite 514
Trenton, New Jersey 08619 Tel: 609.890.3185
Email: [email protected] www.BioNJ.org
Samantha BambergerCoordinator, Programming Operations
Randi BrombergVice President, Communications and
Linda BrownVice President, Strategic Partnerships
& Programs [email protected]
Donna GibbonsSenior Vice President, Operations
Kristin HassanAlliance Manager
Erika HerbstmanSocial Media and Design Manager
Denise MachadoManager, Membership Operations
Debbie MennitoDirector, Talent Services & Events
Kim MintonMembership [email protected]
Cheri PottsOffice Manager
Dana SaccoExecutive [email protected]
Peggy SchellTalent Services and Public Policy
John Slotman Vice President, Government Affairs
Ann WieczkowskiManager, Accounting Services
[email protected] B - Suite 514
Trenton, New Jersey 08619
Debbie HartPresident & CEO
SEE YOU NEXT MONTH AT
BI 2019 IN PHILADELPHIA!
#BIO2019
June 3-6, 2019Philadelphia, PA
2019 BIO INTERNATIONAL CONVENTION IS HOSTED BY:
16,000+ attendees from 67 countries
Projected 50,000+ BIO One-on-One Partnering™ Meetings
150+ innovative education sessions
1,800+ Exhibitors showcasing the latest technology
Discover the next generation of cutting-edge products, therapies, and cures all week long.
The world’s largest global biotechnology partnering event
Visit convention.bio.org/register to register today.
24
Related Documents
